BioRestorative Therapies (FRA:9OF) Interest Expense: €0.00 Mil (TTM As of Mar. 2026)


FRA:9OF BioRestorative Therapies Inc FRA:9OF
51 GF Score
Price €0.34
GF Value €1.28
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BioRestorative Therapies Interest Expense?

BioRestorative Therapies FRA:9OF +4.97% 51 Interest Expense is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:9OF with a GF Score™ of 51/100 and a GF Value™ of €1.28 (Possible Value Trap). The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. BioRestorative Therapies's interest expense for the three months ended in Mar. 2026 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. BioRestorative Therapies's Operating Income for the three months ended in Mar. 2026 was € -2.93 Mil. BioRestorative Therapies's Interest Expense for the three months ended in Mar. 2026 was € 0.00 Mil. BioRestorative Therapies has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

BioRestorative Therapies  (FRA:9OF) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

BioRestorative Therapies's Interest Expense for the three months ended in Mar. 2026 was €0.00 Mil. Its Operating Income for the three months ended in Mar. 2026 was €-2.93 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was €0.00 Mil.

BioRestorative Therapies's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

BioRestorative Therapies had no long-term debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

BioRestorative Therapies Inc has no debt.

BioRestorative Therapies Interest Expense Historical Data

* Premium members only.

The historical data trend for BioRestorative Therapies's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioRestorative Therapies Interest Expense Chart

BioRestorative Therapies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.61 0.00 0.00 0.00 0.00

BioRestorative Therapies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:9OF
51GF Score
BioRestorative Therapies Inc FRA:9OF
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioRestorative Therapies Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of €0.00 Mil mean?
BioRestorative Therapies (FRA:9OF) has a Interest Expense of €0.00 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on BioRestorative Therapies and its competitors.
Is BioRestorative Therapies' Interest Expense too high?
BioRestorative Therapies' current Interest Expense is €0.00 Mil. Overall, BioRestorative Therapies has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioRestorative Therapies' Interest Expense compare to CVKD and JSPR?
BioRestorative Therapies' Interest Expense of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on BioRestorative Therapies and its competitors. BioRestorative Therapies's current Interest Expense is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioRestorative Therapies stock overvalued right now?
Based on GuruFocus' analysis, BioRestorative Therapies (FRA:9OF) is currently considered Possible Value Trap. The stock's GF Value™ is €1.28, compared to a current price of €0.34 — trading 73.6% below its estimated fair value. The current Interest Expense is €0.00 Mil. BioRestorative Therapies' overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For BioRestorative Therapies (FRA:9OF), the current Interest Expense is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioRestorative Therapies (FRA:9OF) Overvalued in 2026?

Based on GuruFocus' analysis, BioRestorative Therapies stock appears to be undervalued. The current stock price of €0.34 is trading 73.6% below its estimated GF Value™ of €1.28. GuruFocus considers BioRestorative Therapies to be Possible Value Trap.

Key valuation signals for FRA:9OF:

  • Interest Expense: €0.00 Mil
  • GF Value™: €1.28 vs. price of €0.34 (73.6% below fair value)
  • GF Score™: 51/100 with 3 warning signs

No single metric tells the full story. See the FRA:9OF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioRestorative Therapies Business Description

Other Exchanges BRTX:USA
Address 40 Marcus Drive, Suite One, Melville, NY, USA, 11747
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
51GF Score

Get the complete analysis for FRA:9OF

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.34
Price
€1.28
GF Value